- Home
- AMBQ vs ZURA Comparison
AMBQ vs ZURA Comparison
Compare AMBQ & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMBQ | ZURA |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 521.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMBQ | ZURA |
|---|---|---|
| Price | $23.91 | $5.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $41.75 | $11.78 |
| AVG Volume (30 Days) | 320.6K | ★ 475.6K |
| Earning Date | 03-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.12 | $0.99 |
| 52 Week High | $43.06 | $7.25 |
Technical Indicators
Market Signals| Indicator | AMBQ | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 46.38 |
| Support Level | $23.30 | $5.62 |
| Resistance Level | $30.15 | $6.99 |
| Average True Range (ATR) | 1.64 | 0.49 |
| MACD | -0.24 | -0.09 |
| Stochastic Oscillator | 1.05 | 34.16 |
Price Performance
Historical ComparisonAbout AMBQ Ambiq Micro Inc.
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.